NCT07038928Recruiting
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 5 Jun 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Bladder cancer
- NCT number
- NCT07038928
What you commit to
- Study type: Observational
- Planned participants: 600
- From 30 Jun 2025 to the primary completion date, 31 Dec 2026
- 16 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participation in any interventional trial since the urothelial bladder cancer diagnosis.
Who the study is looking for
- Age ≥ 18 years;
- Signed ICF, including consent for FFPE tumor tissue sample testing;
- Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
- For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:
- T1 tumor
- High grade/G3 tumor
- CIS (carcinoma in situ)
- Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);
- For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;
- For patients with mBC: mBC diagnosed during 12 months prior to study entry;
- Availability of medical history data;
- Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.